![Martin Leach](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin Leach
Geschäftsführer bei Alloy Therapeutics LLC
Profil
Martin D.
Leach is currently the Chief Operating Officer at Alloy Therapeutics LLC since 2023.
Prior to this, he worked as the Vice President-Information at CuraGen Corp.
Dr. Leach holds a graduate degree from MIT Sloan School of Management and a doctorate degree from Boston University School of Medicine.
Aktive Positionen von Martin Leach
Unternehmen | Position | Beginn |
---|---|---|
Alloy Therapeutics LLC
![]() Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Geschäftsführer | 29.06.2023 |
Ehemalige bekannte Positionen von Martin Leach
Unternehmen | Position | Ende |
---|---|---|
CuraGen Corp.
![]() CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Martin Leach
Boston University School of Medicine | Doctorate Degree |
MIT Sloan School of Management | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
CuraGen Corp.
![]() CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Alloy Therapeutics LLC
![]() Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Commercial Services |